Corcept Therapeutics Incorporated (CORT) Q4 FY25 Earnings Call

Growth remains strong, but approval uncertainty and execution risks temper the commercial opportunity. [3][5][14]

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length42 minutes
EPS$0.20
EPS consensus$0.27
Revenue$207.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CORT earnings ยท Back to CORT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.